Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kurume
Clinical trial register · Japan

Clinical Trials in Kurume, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC22 Pfizer6 Eli Lilly and Company6 Novartis Pharmaceuticals5 Janssen Research & Development, LLC5
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kurume

99 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
UCB BIOSCIENCES, Inc.
Phase 3
200
Kodaira, Kurume, Musashimurayama-shi, Osaka, Setagaya-ku
2026-07-14
Recruiting
Genmab
Phase 3
544
Sapporo, Akashi, Tsu, Takatsuki, Hidaka, Kashiwa, Kawasaki, Kurume
2026-04-03
Recruiting
Novartis Pharmaceuticals
Observational
30
Kurume, Osaka, Suita, Bunkyo Ku
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Nagoya, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun, Hidaka, Sunto-gun,
2026-02-16
Recruiting
Eli Lilly and Company
Phase 2
450
Chikugo, Fukushima, Hachinohe, Hiratsuka, Karatsu, Kodaira, Kumamoto, Kurume
2026-02-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Nagoya, Tōon, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun, Yokohama
2026-01-19
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Bunkyō City, Kumamoto, Kurume, Matsumoto, Sendai, Shinjuku, Suita, Tsukuba
2026-01-09
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Asahikawa, Sapporo, Kobe
2026-01-06
Recruiting
Incyte Corporation
Phase 3
466
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama
2025-12-09
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Kurume, Asahikawa, Sapporo, Yokohama, Sendai, Matsumoto, Ōmura, Kashihara
2025-11-30
Recruiting
Novartis Pharmaceuticals
Phase 3
31
Toyoake, Kurume, Ōtsu, Fuchū
2025-11-27
Recruiting
Incyte Corporation
Phase 2
160
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Sapporo, Sunto-gun
2025-11-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Nagoya, Kashiwa, Tōon, Kurume, Sapporo, Nishinomiya, Yokohama, Sendai
2025-11-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Nagoya, Toyoake, Hirosaki, Tōon, Kurume, Ōta, Himeji, Kobe
2025-10-08
Recruiting
Pfizer
Phase 3
680
Kurume, Kure, Akashi, Kochi, Tsu, Sendai, Ōmura, Beppu-shi
2025-09-29
Recruiting
Sanofi
Phase 3
942
Kōnan, Nagoya, Toyota, Matsuyama, Fukuoka, Iizuka, Kurume, Kure
2025-09-16
Recruiting
Pfizer
Phase 3
6,000
Kurume, Sendai, Beppu-shi, Habikino, Izumisano, Kofu, Fukui, Kyoto
2025-08-25
Recruiting
Pfizer
Phase 3
714
Tōon, Kurume, Otashi, Asahikawa, Kobe, Yokohama, Tsu, Sendai
2025-07-23
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Bunkyō City, Fukuoka, Kagawa, Kashihara, Kobe, Kumamoto, Kurume, Matsumoto-shi
2025-07-02
Active, closed
Bayer
Phase 3
36
Kurume, Himeji, Kobe, Tsukuba, Morioka, Sagamihara, Yokohama, Nankoku
2025-06-30
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Nagoya, Kamogawa, Kitakyushu, Kurume, Minokamo, Maebashi, Yokohama, Nankoku
2025-06-19
Recruiting
Osaka University
Not applicable
450
Matsudo, Urayasu, Kitakyushu, Kurume, Nishinomiya, Isehara, Kamakura, Kawasaki
2025-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Nagoya, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Nagoya, Sakura, Tōon, Kitakyushu, Kurume, Sapporo, Kobe, Kahoku-gun
2025-05-13
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
35
Nagoya, Kashiwa, Kurume, Nishinomiya, Sagamihara, Yokohama, Nankoku, Kyoto
2025-04-21
Active, closed
EyeBiotech Ltd.
Phase 2/3
1,054
Nagoya, Hirosaki, Sakura, Yoshida-gun, Fukuoka, Kurume, Asahikawa, Amagasaki
2025-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Shiwa-gun
2025-04-09
Recruiting
Pfizer
Phase 3
674
Kurume, Sendai, Niigata, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Osaka
2025-04-01
Recruiting
Summit Therapeutics
Phase 3
780
Nagoya, Kurume, Asahikawa, Nishinomiya, Kanazawa, Tokyo, Kumamoto, Kyoto
2025-02-27
Recruiting
Bristol-Myers Squibb
Phase 3
530
Matsuyama, Kurume, Sapporo, Kobe, Kanazawa, Yokohama, Sendai, Kashihara
2025-02-25
Active, closed
Genmab
Phase 3
584
Nagoya, Kurume, Sapporo, Kawasaki, Sendai, Niigata, Okayama, Hidaka
2025-02-07
Recruiting
Takeda
Phase 3
70
Kurume, Bunkyo-ku, Setagaya-Ku
2025-01-22
Recruiting
Hypothermia Versus Normothermia After Extracorporeal Cardiopulmonary Resuscitation for Out-of-hospital Cardiac Arrest
NCT06776549Out-of-hospital Cardiac Arrest (OHCA), ECMO Treatment, Temperature, Post Cardiac Arrest Syndrome
Kagawa University
Not applicable
468
Kurume, Asahikawa, Sapporo, Kakogawa, Kobe, Toyooka, Hitachi-shi, Kita-gun
2025-01-06
Recruiting
Novartis Pharmaceuticals
Observational
30
Ōbu, Toyoake, Kurume, Sapporo, Tsukuba, Kawasaki, Yokohama, Tsu
2024-12-19
Active, closed
Verastem, Inc.
Phase 2
16
Nagoya, Kurume, Tsu, Sendai, Minato
2024-10-30
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
156
Kamogawa, Yoshida, Kurume, Sapporo, Hirakata, Mibu, Musashino, Fukuoka
2024-10-10
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Nakamura-ku,Nagoya, Kashiwa, Kitakyushu, Kurume, Fukuyama-shi, Sapporo, Sagamihara, Yokohama
2024-10-07
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Asahikawa-Shi, Chiba, Chuo-Shi, Fukuoka, Isehara, Izumo, Kurashiki-Shi, Kurume
2024-08-30
Active, closed
TAV-in-SAV in Japanese Patients
NCT06826027Valve-in-valve Procedures
Osaka University
Observational
180
Urayasu, Fukuoka, Kurume, Okayama, Osaka, Suita, Saga, Koshigaya
2024-08-07
Recruiting
ARCAGY/ GINECO GROUP
Phase 3
250
Bunkyō City, Fukushima, Hidaka, Hirosaki, Kashiwa, Kawasaki, Koshigaya, Kurume
2024-07-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ohta, Sapporo, Tsukuba
2024-07-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagakute, Nagoya, Abiko, Kashiwa, Sakura, Kurume, Maebashi, Fukuyama
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Nagoya, Toyoake, Kashiwa, Matsuyam, Fukuoka, Kurume, Ōta, Sapporo
2024-05-24
Active, closed
Takeda
Phase 1/2
28
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Akashi, Shiwa-gun, Sendai
2024-05-20
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Nagoya, Kashiwa-shi, Matsuyama, Kurume, Ota-Shi, Kobe, Kanazawa, Yokohama
2024-02-21
Recruiting
Yonsei University
Phase 2
198
Kurume, Fukushima, Tsu, Sendai, Niigata, Hidaka, Tokushima, Tokyo
2024-01-22
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Kobe, Yokohama, Hirakata
2024-01-18
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
185
Nagakute, Nagoya, Sakura, Kurume, Kōriyama, Sapporo, Kobe, Mito
2024-01-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Sakura, Tōon, Kitakyushu, Kurume, Asahikawa, Sapporo, Kobe, Mukai-awagasaki
2023-12-31
Active, closed
Study of Tamibarotene in Patients With ADPKD
NCT06289998Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugTamibarotene
Rege Nephro Co., Ltd.
Phase 2
70
Kurume, Sapporo, Kamakura, Kawasaki, Kyoto, Bunkyo-ku, Minato-ku, Shinjukuku
2023-12-22
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Nagoya, Kashiwa-shi, Kurume, Kanazawa, Yokohama, Kyoto, Sendai, Ōsaka-sayama
2023-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Toyoake, Hirosaki, Kashiwa, Matsuyama, Fukuoka, Kurume, Ōta, Himeji
2023-12-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Nagoya, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Nagakute, Abiko, Kashiwa, Sakura, Matsuyama, Kitakyushu, Kurume, Maebashi
2023-10-25
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Nagakute, Chiba, Kamogawa, Kashiwa-shi, Kurume, Ōgaki, Maebashi, Shibukawa
2023-09-18
Active, closed
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
NCT05914155Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic
DrugRituximab
Shoichi Maruyama MD PhD
Phase 3
88
Anjo, Kasugai, Kōnan, Nagoya, Toyoake, Urayasu, Fukuoka, Kurume
2023-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
39
Toyoake, Kurume, Otashi, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-06-13
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Kurume, Akashi, Hirakata, Kashiwa, Nagoya, Ōsaka-sayama, Sapporo, Sendai
2023-06-01
Recruiting
Eli Lilly and Company
Phase 3
595
Hamamatsu, Kurume, Mitaka, Miyagi-gun, Niigata, Osaka, Shinjuku-ku, Ube
2023-02-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
377
Toyoake, Kurume, Ōta, Sapporo, Yokohama, Natori-shi, Sendai, Kurashiki
2023-02-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Nagoya, Matsuyama, Kurume, Takarazuka, Kanazawa, Yokohama, Natori-shi, Sendai
2023-02-06
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Kurume, Shinjuku Ku
2022-12-19
Active, closed
Kringle Pharma, Inc.
Phase 3
62
Toyoake, Fukuoka, Kurume, Kamigyō-ku, Sendai, Kurashiki, Chiyoda-ku, Minato-Ku
2022-12-01
By invitation
Ionis Pharmaceuticals, Inc.
Phase 3
1,400
Kurume-Shi, Fukuoka, Hamamatsu, Kumamoto, Kurume, Matsumoto, Okayama, Osaka
2022-11-30
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Chūōku, Himeji, Hirakata, Kanagawa, Kurashiki, Kurume, Matsusaka, Niigata
2022-08-05
Recruiting
Astellas Pharma Inc
Phase 1
681
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Yokohama, Sendai, Niigata
2022-06-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai
2022-03-24
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Nagoya, Toyoake, Urayasu, Kurume, Amagasaki, Kobe, Tsukuba, Kanazawa
2022-03-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Kashiwa, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun Yahaba-cho
2022-02-03
Recruiting
ARCAGY/ GINECO GROUP
Phase 2
390
Tokyo, Kashiwanoha, Kurume, Tsukuba, Niigata, Kita-ku, Shimotsuke, Ehime
2022-02-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Shiwa-gun Yahaba-cho, Kawasaki
2021-12-13
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gunma, Hyōgo, Kanagawa, Kobe, Kurume, Nagoya, Niigata, Osaka
2021-11-17
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Bunkyō City, Gunma, Ikoma, Kurume, Saitama Shi, Sendai, Setagaya Ku, Tsu
2021-10-18
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Kurume, Suita, Chuo Ku, Minato-Ku, Shinjuku-Ku, Matsuyama, Nagoya, Niigata
2021-10-11
Active, closed
Eli Lilly and Company
Phase 3
874
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Sapporo, Akashi, Kobe
2021-10-04
Active, closed
Novartis Pharmaceuticals
Phase 2
36
Narita, Kurume, Ohtake, Nishinomiya, Kanazawa, Isehara, Yokohama, Sendai
2021-05-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Akashi
2021-01-10
Active, closed
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
NCT04192747Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Elixir Medical Corporation
Not applicable
445
Kitakyushu, Kurume, Sapporo, Tsuchiura, Kagoshima, Kamakura, Kawasaki-shi, Yokohama
2020-12-16
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Bunkyō City, Chūōku, Fukuoka, Himeji, Hirakata, Kanazawa, Kashiwa, Kurume
2020-09-30
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
70
Chiba, Kashiwa, Matsuyama, Fukuoka, Kurume, Hiroshima, Sapporo, Akashi
2020-09-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Kurume, Kobe, Yokohama, Hirakata, Takatsuki, Fukuoka, Niigata, Osaka
2020-07-06
Active, closed
Actelion
Phase 3
935
Bunkyō City, Fukuoka, Hiroshima, Kagoshima, Kanagawa, Kanazawa, Kobe, Kurume
2020-06-30
Recruiting
Eisai Co., Ltd.
Phase 1
18
Hakata, Kurume, Yuhu, Bukyo-ku, Mintato-ku, Shinjuku-ku, Kofu, Kyoto
2020-02-27
Active, closed
BeOne Medicines
Phase 3
955
Toyohashi, Kurume, Sapporo
2020-01-16
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Tsurumai-cho, Fukuoka, Kurume, Kita-gun, Nankoku, Matsumoto, Kashihara, Suita
2019-11-26
Active, closed
Eisai Co., Ltd.
Phase 1/2
125
Nagoya, Kashiwa, Matsuya, Kurume, Akashi, Yokohama, Sendai, Chuo Ku
2019-09-05
Active, closed
BeOne Medicines
Phase 3
510
Nagoya, Toyohashi, Chiba, Kurume, Hiroshima, Yokohama, Kumamoto, Kyoto
2019-08-20
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Akashi, Kawasaki, Kamigyō-ku
2019-07-11
Active, closed
Takeda
Phase 1
53
Nagoya, Toyoake, Kashiwa, Kurume, Sapporo, Akashi, Kanazawa, Yokohama
2019-02-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Akashi, Himeji
2018-08-21
Active, closed
pharmaand GmbH
Phase 3
1,097
Tsukuba, Kashiwa, Kurume, Yokohama, Maebashi, Ota-shi, Naka, Akashi
2018-05-14
Active, closed
Eli Lilly and Company
Phase 3
5,637
Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Ōta, Hiroshima, Sapporo
2017-07-12
Active, closed
Regeneron Pharmaceuticals
Phase 1
146
Nagoya, Kurume, Ōta, Kobe, Kanazawa, Sagamihara, Yokohama, Sasebo
2017-06-21
Active, closed
Pfizer
Phase 3
296
Nagoya, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai, Osaka
2017-04-27
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Chūōku, Hyōgo, Kashiwa, Kurume, Nagoya, Niigata, Osaka, Tokyo
2016-05-24
Active, closed
Eli Lilly and Company
Phase 3
545
Nagoya, Kashiwa, Tōon, Kurume, Asahikawa, Akashi, Amagashiki, Himeji
2015-05-06
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Fukuoka, Kanazawa, Kashiwa, Kita-Gun, Kumamoto, Kurume, Matsuyama, Miyazaki
2014-11-26
Active, closed
Eli Lilly and Company
Phase 3
669
Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Sapporo, Nishinomiya, Kawasaki
2014-07-22
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Hirakata, Hokkaido, Itabashi Ku, Kobe, Kurume, Matsumoto, Ōita, Takamatsu
2007-06-21
Rows per page Showing 1–99 of 99
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kurume

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 99 of those studies with a site in Kurume.

How many clinical trials are recruiting in Kurume?

47 of the 99 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 51 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kurume), 99 studies
PhaseStudiesRecruitingShare
Phase 3663066.7%
Phase 211611.1%
Phase 1848.1%
Observational646.1%
Not applicable323%
Phase 1/2303%
Phase 2/3212%

Most active sponsors

Lead sponsors with the most studies (Kurume)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC2211
Eli Lilly and Company62
Pfizer65
Janssen Research & Development, LLC50
Novartis Pharmaceuticals53
Alnylam Pharmaceuticals32
Bristol-Myers Squibb33
Kyowa Kirin Co., Ltd.32
Takeda31
ARCAGY/ GINECO GROUP22
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.